Publications
36
Citations
47
Est. group size
~12
Recurring co-author estimate
Active years
17
Publishing since 2009
Bhuvaneswari Ramaswamy's research focuses on breast cancer biology, particularly mechanisms of drug resistance (such as resistance to tamoxifen and paclitaxel) and potential new therapeutic targets. Work spans molecular and genomic analyses (multi-omics, epigenetics), signaling pathways like PI3K/AKT and Hedgehog, and immune-based approaches including tumor immunotherapy and macrophage-targeted strategies in triple-negative and inflammatory breast cancer. Much of the output includes clinical outcome studies and translational data linked to specific breast cancer subtypes.
Publication output was minimal to absent in the earlier part of the decade but rose sharply starting in 2022-2023, followed by continued but somewhat reduced activity through 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Invasive lobular carcinoma: integrated multi-omics analysis reveals silencing of Argininosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance
Cell Death and Disease · 2025
- Sulfatase 2 inhibition sensitizes triple-negative breast cancer cells to paclitaxel through augmentation of extracellular ATP
Cancer Biology & Therapy · 2025
- Invasive lobular carcinoma integrated multi-omics analysis reveals silencing of Arginosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Abstract P3-02-18: Multi omics reveals silencing of Argininosuccinate synthase and upregulation of nucleotide biosynthesis in tamoxifen resistance invasive lobular carcinoma
Clinical Cancer Research · 2025
- Abstract PO3-03-05: Clinical outcomes in early-stage TNBC according to HER2-low status
Cancer Research · 2024
- Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in Breast Cancer
2023
- Data from Slit2 Inhibits Breast Cancer Metastasis by Activating M1-Like Phagocytic and Antifibrotic Macrophages
2023
- Data from Slit2 Inhibits Breast Cancer Metastasis by Activating M1-Like Phagocytic and Antifibrotic Macrophages
2023
- Supplementary Methods, Tables 1-2, Figures 1-4 from Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway
2023
- Supplementary Data from Slit2 Inhibits Breast Cancer Metastasis by Activating M1-Like Phagocytic and Antifibrotic Macrophages
2023
- Supplementary Data from Slit2 Inhibits Breast Cancer Metastasis by Activating M1-Like Phagocytic and Antifibrotic Macrophages
2023
- Supplementary Figures 1-6, Tables 1-15, Methods from Epigenetic Silencing Mediated through Activated PI3K/AKT Signaling in Breast Cancer
2023
- Supplementary Methods, Tables 1-2, Figures 1-4 from Hedgehog Signaling Is a Novel Therapeutic Target in Tamoxifen-Resistant Breast Cancer Aberrantly Activated by PI3K/AKT Pathway
2023
- Data from Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON
2023
- Supplementary Data from Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON
2023
- Cancer Research×5
- bioRxiv (Cold Spring Harbor Laboratory)×2
- Cell Death and Disease×1
- Breast Cancer Research×1
- Cancer Biology & Therapy×1
- H. B. Day
Medicine · Indiana University
- Alain Bopda Waffo
Medicine · Indiana University
- David W. Wood
Medicine · The Ohio State University
- Donghui Ma
Medicine · Purdue University West Lafayette
- Jonathan P. Butchar
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile